GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Total Liabilities

Cellectis (XPAR:ALCLS) Total Liabilities : €240.18 Mil (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Total Liabilities?

Cellectis's Total Liabilities for the quarter that ended in Jun. 2024 was €240.18 Mil.

Cellectis's quarterly Total Liabilities increased from Dec. 2023 (€228.86 Mil) to Mar. 2024 (€242.78 Mil) but then declined from Mar. 2024 (€242.78 Mil) to Jun. 2024 (€240.18 Mil).

Cellectis's annual Total Liabilities declined from Dec. 2021 (€128.86 Mil) to Dec. 2022 (€127.70 Mil) but then increased from Dec. 2022 (€127.70 Mil) to Dec. 2023 (€228.86 Mil).


Cellectis Total Liabilities Historical Data

The historical data trend for Cellectis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Total Liabilities Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.80 132.03 128.86 127.70 228.86

Cellectis Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.02 125.16 228.86 242.78 240.18

Cellectis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cellectis's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=142.267+(65.466+18.965
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.145+2.017)
=228.86

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=306.526-77.665
=228.86

Cellectis's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=148.299+(72.349+17.495
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+2.038)
=240.18

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=378.24-138.059
=240.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cellectis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines